Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
79 hedge funds and large institutions have $528M invested in Apellis Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 34 increasing their positions, 21 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
62% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 21
8% more funds holding
Funds holding: 73 → 79 (+6)
0.93% more ownership
Funds ownership: 51.96% → 52.88% (+0.93%)
17% less capital invested
Capital invested by funds: $639M → $528M (-$111M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$7.67M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$5.47M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.1M |
| 4 |
Millennium Management
New York
|
+$3.95M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.3M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$3.7M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.59M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.88M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$1.22M |
APLS Hedge Fund Activity: Q3 2018 in Review
79 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q3 2018, worth a combined $528M — down 17% from $639M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new APLS positions and 6 closed out — a net gain of 6 holders — while 34 added to existing stakes and 21 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $7.67M. The largest seller was Fidelity Investments, cutting an estimated $14.3M.
- 79 institutional investors held Apellis Pharmaceuticals (APLS) as of Q3 2018, up from 73 in Q2 2018.
- Funds reported $528M of Apellis Pharmaceuticals stock for Q3 2018, down 17% quarter-over-quarter.
- 12 funds opened new Apellis Pharmaceuticals positions in Q3 2018 and 6 closed out, a net change of +6 holders.
- The largest Apellis Pharmaceuticals buyer in Q3 2018 was Victory Capital Management, an estimated $7.67M added.
- The largest Apellis Pharmaceuticals seller in Q3 2018 was Fidelity Investments, an estimated $14.3M sold.
Based on aggregated 13F filings for Q3 2018.